What the label lists and what reports show
Faricimab side effects
Faricimab's FDA label: “The most common adverse reactions (≥ 5%) reported in patients receiving VABYSMO were cataract (15%) and conjunctival hemorrhage (8%).” FAERS holds 8,057 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is retinal thickening (1,020 reports).
- No generic listed
Check it at the source: the faricimab FDA label on DailyMed (effective April 15, 2026); the FDA FAERS public dashboard.
What does the label list?
From the label: adverse reactionsThe most common adverse reactions (≥ 5%) reported in patients receiving VABYSMO were cataract (15%) and conjunctival hemorrhage (8%).
Table 1: Common Adverse Reactions (≥ 1%)
| Reaction | AMD N=664 | DME N=1,262 | RVO N=641 | AMD N=662 | DME N=625 | RVO N=635 |
|---|---|---|---|---|---|---|
| Cataract | 3% | 15% | < 1% | 2% | 12% | 1% |
| Conjunctival hemorrhage | 7% | 8% | 3% | 8% | 7% | 4% |
| Vitreous detachment | 3% | 5% | 2% | 3% | 4% | 2% |
| Vitreous floaters | 3% | 4% | 2% | 2% | 3% | 2% |
| Intraocular pressure increased | 3% | 4% | 1% | 2% | 3% | 3% |
| Eye pain | 3% | 3% | < 1% | 3% | 3% | < 1% |
| Intraocular inflammation Including iridocyclitis, iritis, uveitis, vitritis | 2% | 1% | 1% | 1% | 1% | < 1% |
| Eye irritation | 1% | < 1% | < 1% | < 1% | 1% | < 1% |
| Lacrimation increased | 1% | 1% | 0 | 1% | < 1% | < 1% |
| Ocular discomfort | 1% | 1% | < 1% | < 1% | < 1% | < 1% |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
From the label: adverse reactions, continuedThe following potentially serious adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Contraindications (4) ] Endophthalmitis and retinal detachments [see Warnings and Precautions (5.1) ] Increase in intraocular pressure [see Warnings and Precautions (5.2) ] Thromboembolic events [see Warnings and Precautions (5.3) ] Retinal Vasculitis and/or Retinal Vascular Occlusion [see Warnings and Precautions (5.4) ] The most common adverse reactions (≥ 5%) reported in patients receiving VABYSMO were cataract (15%) and conjunctival hemorrhage (8%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials of the same or another drug and may not reflect the rates observed in practice. The data described below reflect exposure to VABYSMO in 2,567 patients, which constituted the safety population in six Phase 3 studies [see Clinical Studies (14.1 , 14.2 , 14.3) ].
Source: FDA drug label, Genentech, Inc., effective April 15, 2026 (SPL set 04cc9ef7-c02a-4e92-a655-0062674e8487), via openFDA; the full label on DailyMed
What do FAERS reports show?
8,057 reports list faricimab among the medicines taken, each a report of something that happened, not proof the medicine caused it; 463 are coded as a death and 496 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2024 (3,756, against a median of 3 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens. Of the 21 reactions below, 12 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Faricimab: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions